On March 25, 2025, Acurx Pharmaceuticals, Inc. was notified by Nasdaq that it does not meet the minimum stockholders equity requirement of $2,500,000 for continued listing, based on its 2024 Annual Report, and has until May 9, 2025, to submit a Compliance Plan to regain compliance.